Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...
The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...
The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...
Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer ...
Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...
In a groundbreaking review published in Current Molecular Pharmacology, a team led by Dr. Jhi Biau Foo from Taylor’s University unveils the pivotal role of mutant p53 (mutp53) in driving cancer ...
Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results